Getting Started

Who Can Take Weight Loss Injections

Whether you are wondering if you might qualify for Mounjaro or Wegovy in the UK or trying to make sense of why eligibility differs between the NHS and private prescribing, this guide explains the criteria a prescriber uses, the situations where weight-loss injections are not appropriate, and what to expect from a clinical assessment. LetsLoseWeight is an independent comparison site; we are not affiliated with any pharmacy or provider, and only a qualified prescriber can decide whether a specific medicine is suitable for you.

Two different eligibility frameworks

Weight-loss injection eligibility in the UK is split between two systems with very different criteria:

  • The licensed indication (set by the MHRA when each medicine is approved) — broader. This is the rule that private prescribers in the UK work to.
  • NHS access criteria (set by NICE) — narrower. This sets who the NHS will fund for treatment.

A patient might qualify privately and not on the NHS, or vice versa. Both are legitimate. The right route depends on your situation, your priorities, and what your prescriber recommends.

Private (licensed) eligibility — Mounjaro and Wegovy

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) share a similar licensed indication for weight management in adults:

  • BMI of 30 or above (obesity), or
  • BMI of 27 or above (overweight) plus at least one weight-related health condition, such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or osteoarthritis.

Treatment is licensed as an adjunct to a reduced-calorie diet and increased physical activity — meaning the medication is intended to support lifestyle change, not replace it.

Most regulated UK online pharmacies will offer Mounjaro or Wegovy to patients who meet the licensed criteria, subject to a clinical assessment. Some providers apply slightly stricter rules — for example a higher BMI threshold or additional health checks — at their own discretion.

NHS eligibility

NHS access to weight-loss injections is set by NICE technology appraisals. The criteria are higher than the licensed indication and the access process is more structured.

Mounjaro on the NHS — NICE TA1026

NICE TA1026 (December 2024) recommends tirzepatide (Mounjaro) for adults with:

  • A BMI of at least 35, and
  • At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease).

A reduction of 2.5 in the BMI threshold applies to people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

NHS England is rolling tirzepatide out in phases through primary care over three years. In the early phases, only patients meeting more restrictive priority criteria are eligible — typically those with a higher BMI and a greater burden of weight-related comorbidities (NHS England interim commissioning guidance).

Wegovy on the NHS — NICE TA875

NICE TA875 (March 2023) recommends semaglutide (Wegovy) for adults within a specialist NHS weight management service, only if:

  • They have a BMI of at least 35 with at least one weight-related comorbidity, or
  • A BMI of 30–34.9 and meet the criteria for referral to specialist services.

NHS Wegovy treatment is capped at two years. The same 2.5 BMI reduction applies for the ethnic backgrounds listed above.

Who is not suitable for weight-loss injections

Even if BMI criteria are met, weight-loss injections are not appropriate for some people. The summary of product characteristics for each medicine lists contraindications and cautions; below is a non-exhaustive overview of common reasons a prescriber may decline to prescribe.

Contraindications (medicine should not be used)

  • Personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 (MEN 2) — listed for both Mounjaro and Wegovy.
  • Hypersensitivity to the active ingredient or any of the excipients.
  • Pregnancy — neither medicine is licensed in pregnancy. People who become pregnant during treatment are advised to stop the medicine and discuss with their prescriber.

Cautions (extra clinical judgement needed)

  • Type 1 diabetes — these medicines are not licensed for type 1 diabetes.
  • Severe gastrointestinal disease — including severe gastroparesis, where slowed gastric emptying could worsen symptoms.
  • History of pancreatitis — usually a reason for caution and shared decision-making.
  • Diabetic retinopathy — close monitoring is advised in people with type 2 diabetes.
  • Significant kidney or liver impairment — prescribers may adjust monitoring or avoid the medicine depending on severity.
  • Breastfeeding — neither medicine is licensed during breastfeeding.

This is not a complete list. Always disclose your full medical history and current medications during your assessment so the prescriber can make an informed decision. The full lists are in the Mounjaro SmPC and Wegovy SmPC on the EMC.

Age criteria

  • Mounjaro is licensed in adults aged 18 and over for weight management. Use in adolescents (aged 12 and over) for weight management is licensed in some markets but is being rolled out cautiously in the UK; private prescribing in under-18s is unusual.
  • Wegovy is licensed in adults aged 18 and over for weight management, and in adolescents aged 12 and over with a BMI at the 95th percentile or above for age and sex.

For NHS access, both NICE TAs apply only to adults.

What providers usually check

A clinical assessment for a private prescription typically covers:

  • Identity and age verification — usually a photo ID and proof of address.
  • Height, weight and BMI — calculated from current measurements, usually with photographic verification.
  • Medical history — including diabetes, thyroid disease, pancreatitis, gallbladder disease, eating disorders, mental health conditions, pregnancy plans, and any history of bariatric surgery.
  • Current medications — particularly other diabetes medicines, blood pressure medicines, and any drugs that might interact.
  • Lifestyle context — diet, activity, alcohol intake, and previous weight-loss attempts.
  • Goals — what the patient is hoping to achieve and over what timeframe.

A good prescriber will decline to prescribe if they consider the medicine unsuitable, even if the basic BMI threshold is met. That is a quality signal, not a problem — it means the assessment is being done properly. UK pharmacies regulated by the General Pharmaceutical Council (GPhC) are required to operate this way.

Private vs NHS — which is right?

Private and NHS routes are not direct substitutes. Each has trade-offs.

Private NHS
Eligibility threshold Lower (BMI 30, or 27 with comorbidity) Higher (BMI 35 with comorbidity)
Speed of access Days to weeks Months, with phased rollout still in progress
Cost Patient pays in full NHS-funded (no patient cost)
Wraparound support Varies by provider Structured (required by NICE)
Treatment duration Long-term, while clinically appropriate Wegovy capped at 2 years; Mounjaro continues with review
Choice of medicine Patient and prescriber decide together NHS service typically offers what is available

Anyone considering weight-loss injections should discuss the options with their GP. Even patients pursuing the private route benefit from involving their NHS GP — most regulated UK pharmacies will share prescription details with the GP if the patient consents, which keeps the broader medical record complete.

Frequently asked questions

Can I get weight-loss injections without a prescription?
No. Both Mounjaro and Wegovy are prescription-only medicines in the UK. Anyone offering them without a prescription is operating outside the regulated supply chain. Risks include counterfeit product and no clinical oversight — see the MHRA's public warning.

My BMI is just under 30 — can I still qualify?
You may qualify privately if your BMI is 27 or above and you have a weight-related health condition. Below 27, the medicines are not within their licensed indication and a regulated UK prescriber will normally decline to prescribe.

Will my GP prescribe Mounjaro or Wegovy?
On the NHS, GPs can now prescribe tirzepatide (Mounjaro) for eligible patients under TA1026, but rollout is phased and many areas have waiting lists. For Wegovy, NHS prescribing is through specialist weight management services rather than primary care. Privately, regulated UK online pharmacies are the most common route.

Do I need to fail other treatments first?
The licensed indication does not strictly require previous treatment attempts. NICE-recommended NHS access historically expects engagement with structured weight management services first, but the specific pathway depends on local commissioning.

What if I have type 2 diabetes?
Both Mounjaro and Wegovy can be appropriate for people with type 2 diabetes, but the route may differ. Mounjaro has a separate NHS recommendation for type 2 diabetes (NICE TA924) at lower doses. Discuss with your GP or diabetes team.

Next steps

Sources

This guide is for general information only and is not a substitute for professional medical advice. Eligibility decisions are made by qualified prescribers based on individual clinical assessment.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Guides
Who Can Take Weight Loss Injections? UK Eligibility | LetsLoseWeight